Minocycline Susceptibility of Carbapenem-Resistant Acinetobacter baumannii Blood Isolates from a Single Center in Korea: Role of tetB in Resistance
- PMID: 40183657
- PMCID: PMC11972901
- DOI: 10.3947/ic.2024.0110
Minocycline Susceptibility of Carbapenem-Resistant Acinetobacter baumannii Blood Isolates from a Single Center in Korea: Role of tetB in Resistance
Abstract
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) represents a devastating and growing global threat, calling for new antibiotic treatments. In Korea, the challenge of treating CRAB is compounded by high nosocomial acquisition rates and limited availability of novel antibiotics. Minocycline, a semisynthetic tetracycline derivative, has been proposed as a therapeutic option for CRAB infections. Nonsusceptibility to minocycline may occur through the efflux pump, TetB. The prevalence of tetB in A. baumannii has increased, along with higher minocycline minimum inhibitory concentrations (MICs). We aimed to evaluate minocycline susceptibility rates in clinical strains of CRAB, and the association between tetB carriage and minocycline susceptibility across different genotypes.
Materials and methods: Representative CRAB blood isolates were collected from Asan Medical Center, Seoul. Minocycline susceptibility was assessed using the Clinical and Laboratory Standards Institute (CLSI) breakpoint (≤4 mg/L) and the proposed pharmacokinetics (PK)/pharmacodynamics (PD) breakpoint (≤1 mg/L). Tigecycline was used as a comparator, and its susceptibility breakpoint for Enterobacterales defined by EUCAST was applied (≤0.5 mg/L). The presence of tetB was detected by PCR, and multilocus sequence typing (MLST) was performed using seven housekeeping genes.
Results: Of the 160 CRAB blood isolates, 83.8% were susceptible to minocycline by the CLSI criteria, and 50.6% were PK-PD susceptible by the PK-PD criteria. The minocycline minimum inhibitory concentration (MIC)₅₀/MIC₉₀ was 1/8 mg/L. tetB was present in 49% of isolates and was associated with a higher minocycline MIC (MIC₅₀/₉₀ 2/8 mg/L vs. 1/2 mg/L). No clear correlation was observed between tetB positivity and tigecycline MIC. Nine MLSTs were identified, with significant differences in tetB carriage rates between the major sequence types. Notably, ST191, associated with non-tetB carriage and greater susceptibility to minocycline, declined over the study period (P=0.004), while ST451, associated with tetB carriage, increased.
Conclusion: tetB was present in 49% of CRAB isolates and was associated with higher MICs and non-susceptibility by both CLSI and PK-PD criteria. However, absence of tetB was not a reliable predictor of minocycline PK-PD susceptibility. Additionally, shifts over time towards genotypes with reduced minocycline susceptibility were observed. Further research is needed to correlate these findings with clinical outcomes and identify additional resistance mechanisms.
Keywords: Acinetobacter baumannii; Efflux pump; Minocycline; Resistance; tetB.
© 2025 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, The Korean Society for AIDS, and Korean Society of Pediatric Infectious Diseases.
Conflict of interest statement
HS is ethics editor and SOL is editorial board of
Similar articles
-
Minocycline Susceptibility and tetB Gene in Carbapenem-Resistant Acinetobacter baumannii in Taiwan.Infect Drug Resist. 2022 May 2;15:2401-2408. doi: 10.2147/IDR.S357344. eCollection 2022. Infect Drug Resist. 2022. PMID: 35528186 Free PMC article.
-
Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii.Int J Antimicrob Agents. 2018 Sep;52(3):404-406. doi: 10.1016/j.ijantimicag.2018.04.006. Epub 2018 Apr 14. Int J Antimicrob Agents. 2018. PMID: 29665446
-
[Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates].Enferm Infecc Microbiol Clin. 2006 Feb;24(2):77-80. doi: 10.1157/13085012. Enferm Infecc Microbiol Clin. 2006. PMID: 16545313 Spanish.
-
Susceptibility profile of bla OXA-23 and metallo-β-lactamases co-harbouring isolates of carbapenem resistant Acinetobacter baumannii (CRAB) against standard drugs and combinations.Front Cell Infect Microbiol. 2023 Jan 6;12:1068840. doi: 10.3389/fcimb.2022.1068840. eCollection 2022. Front Cell Infect Microbiol. 2023. PMID: 36683677 Free PMC article.
-
Detection of efflux pump genes in multiresistant Acinetobacter baumannii ST2 in Iran.Acta Microbiol Immunol Hung. 2021 Feb 2;68(2):113-120. doi: 10.1556/030.2021.01314. Print 2021 Jun 21. Acta Microbiol Immunol Hung. 2021. PMID: 33533731
References
-
- Centers for Disease Control and Prevention (CDC) 2019 antibiotic resistance threats report. [Accessed 15 September 2024]. Available at: https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index....
-
- Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226–240. - PubMed
-
- Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391–400. - PubMed
-
- Kaye KS, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett D, Patel G, Calfee D, Leibovici L, Power L, Munoz-Price S, Stevenson K, Susick L, Latack K, Daniel J, Chiou C, Divine GW, Ghazyaran V, Pogue JM. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid. 2023;2:10.1056/evidoa2200131 - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases